|
1
|
Li C, Hampson IN, Hampson L, Kumar P,
Bernabeu C and Kumar S: CD105 antagonizes the inhibitory signaling
of transforming growth factor beta1 on human vascular endothelial
cells. FASEB J. 14:55–64. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gougos A and Letarte M: Primary structure
of endoglin, an RGD-containing glycoprotein of human endothelial
cells. J Biol Chem. 265:8361–8364. 1990.PubMed/NCBI
|
|
3
|
Barbara NP, Wrana JL and Letarte M:
Endoglin is an accessory protein that interacts with the signaling
receptor complex of multiple members of the transforming growth
factor-beta superfamily. J Biol Chem. 274:584–594. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li C, Guo B, Wilson PB, Stewart A, Byrne
G, Bundred N and Kumar S: Plasma levels of soluble CD105 correlate
with metastasis in patients with breast cancer. Int J Cancer.
89:122–126. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duff SE, Li C, Garland JM and Kumar S:
CD105 is important for angiogenesis: Evidence and potential
applications. FASEB J. 17:984–992. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marioni G, D'Alessandro E, Giacomelli L
and Staffieri A: CD105 is a marker of tumour vasculature and a
potential target for the treatment of head and neck squamous cell
carcinoma. J Oral Pathol Med. 39:361–367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Minhajat R, Mori D, Yamasaki F, Sugita Y,
Satoh T and Tokunaga O: Organ-specific endoglin (CD105) expression
in the angiogenesis of human cancers. Pathol Int. 56:717–723. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muniz C, Teodosio C, Mayado A, Amaral AT,
Matarraz S, Barcena P, Sanchez ML, Alvarez-Twose I, Diez-Campelo M,
Garcia-Montero AC, et al: Ex vivo identification and
characterization of a population of CD13high
CD105+ CD45− mesenchymal stem cells in human
bone marrow. Stem Cell Res Ther. 6:1692015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Odabas S, Sayar F, Guven G,
Yanikkaya-Demirel G and Piskin E: Separation of mesenchymal stem
cells with magnetic nanosorbents carrying CD105 and CD73 antibodies
in flow-through and batch systems. J Chromatogr B Analyt Technol
Biomed Life Sci. 861:74–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cavar S, Jelasic D, Seiwerth S, Milosevic
M, Hutinec Z and Misic M: Endoglin (CD 105) as a potential
prognostic factor in neuroblastoma. Pediatr Blood Cancer.
62:770–775. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou Y, Gu H, Xu Y, Li F, Kuang S, Wang Z,
Zhou X, Ma H, Li P, Zheng Y, et al: Targeted antiangiogenesis gene
therapy using targeted cationic microbubbles conjugated with CD105
antibody compared with untargeted cationic and neutral
microbubbles. Theranostics. 5:399–417. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Damron TA, Ward WG and Stewart A:
Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National cancer
data base report. Clin Orthop Relat Res. 459:40–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Savage SA and Mirabello L: Using
epidemiology and genomics to understand osteosarcoma etiology.
Sarcoma. 2011:5481512011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Allison DC, Carney SC, Ahlmann ER,
Hendifar A, Chawla S, Fedenko A, Angeles C and Menendez LR: A
meta-analysis of osteosarcoma outcomes in the modern medical era.
Sarcoma. 2012:7048722012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gibbs CP, Kukekov VG, Reith JD,
Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN and
Steindler DA: Stem-like cells in bone sarcomas: Implications for
tumorigenesis. Neoplasia. 7:967–976. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reubi JC: Peptide receptors as molecular
targets for cancer diagnosis and therapy. Endocr Rev. 24:389–427.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiang Z, Yang X, Xu J, Lai W, Wang Z, Hu
Z, Tian J, Geng L and Fang Q: Tumor detection using magnetosome
nanoparticles functionalized with a newly screened EGFR/HER2
targeting peptide. Biomaterials. 115:53–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alexander-Bryant AA, Zhang H, Attaway CC,
Pugh W, Eggart L, Sansevere RM, Andino LM, Dinh L, Cantini LP and
Jakymiw A: Dual peptide-mediated targeted delivery of bioactive
siRNAs to oral cancer cells in vivo. Oral Oncol. 72:123–131. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma Y, Zhao S, Shen S, Fang S, Ye Z, Shi Z
and Hong A: A novel recombinant slow-release TNF α-derived peptide
effectively inhibits tumor growth and angiogensis. Sci Rep.
5:135952015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Czapla J, Matuszczak S, Wisniewska E,
Jarosz-Biej M, Smolarczyk R, Cichon T, Glowala-Kosinska M, Sliwka
J, Garbacz M, Szczypior M, et al: Human cardiac mesenchymal stromal
cells with CD105+CD34− phenotype enhance the
function of post-infarction heart in mice. PLoS One.
11:e1587452016. View Article : Google Scholar
|
|
21
|
Yamamoto M, Nakata H, Hao J, Chou J,
Kasugai S and Kuroda S: Osteogenic potential of mouse
adipose-derived stem cells sorted for CD90 and CD105 in vitro. Stem
Cells Int. 2014:5763582014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan W, Li J, Wang Y, Pan J, Li S, Zhu L,
Guo C and Yan Z: CD105 promotes chondrogenesis of synovium-derived
mesenchymal stem cells through Smad2 signaling. Biochem Biophys Res
Commun. 474:338–344. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li DY, Sorensen LK, Brooke BS, Urness LD,
Davis EC, Taylor DG, Boak BB and Wendel DP: Defective angiogenesis
in mice lacking endoglin. Science. 284:1534–1537. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takase Y, Kai K, Masuda M, Akashi M and
Tokunaga O: Endoglin (CD105) expression and angiogenesis status in
small cell lung cancer. Pathol Res Pract. 206:725–730. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miyata Y, Mitsunari K, Asai A, Takehara K,
Mochizuki Y and Sakai H: Pathological significance and prognostic
role of microvessel density, evaluated using CD31, CD34, and CD105
in prostate cancer patients after radical prostatectomy with
neoadjuvant therapy. Prostate. 75:84–91. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luo H, England CG, Shi S, Graves SA,
Hernandez R, Liu B, Theuer CP, Wong HC, Nickles RJ and Cai W: Dual
targeting of tissue factor and CD105 for preclinical PET imaging of
pancreatic cancer. Clin Cancer Res. 22:3821–3830. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Hong H, Severin GW, Engle JW,
Yang Y, Goel S, Nathanson AJ, Liu G, Nickles RJ, Leigh BR, et al:
ImmunoPET and near-infrared fluorescence imaging of CD105
expression using a monoclonal antibody dual-labeled with
89Zr and IRDye 800CW. Am J Transl Res. 4:333–346.
2012.PubMed/NCBI
|
|
28
|
Ma Z, Qin H, Chen H, Yang H, Xu J, Yang S,
Hu J and Xing D: Phage display-derived oligopeptide-functionalized
probes for in vivo specific photoacoustic imaging of osteosarcoma.
Nanomedicine. 13:111–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee JS and Tung CH: Osteotropic cancer
diagnosis by an osteocalcin inspired molecular imaging mimetic.
Biochim Biophys Acta. 1830:4621–4627. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun X, Niu G, Yan Y, Yang M, Chen K, Ma Y,
Chan N, Shen B and Chen X: Phage display-derived peptides for
osteosarcoma imaging. Clin Cancer Res. 16:4268–4277. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheon EP, Hong JH and Han HK: Enhanced
cellular uptake of Ara-C via a peptidomimetic prodrug,
L-valyl-ara-C in Caco-2 cells. J Pharm Pharmacol. 58:927–932. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma P, Yu H, Zhang X, Mu H, Chu Y, Ni L,
Xing P, Wang Y and Sun K: Increased active tumor targeting by an
αvβ3-targeting and cell-penetrating bifunctional peptide-mediated
dendrimer-based conjugate. Pharm Res. 34:121–135. 2017. View Article : Google Scholar : PubMed/NCBI
|
